원일약품

비상장계속사업자

WONIL Medical CO. LTD

이한우

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

원일약품

Business Reg. No. 2048134872 · CEO 이한우

I.Investment Overview

Target원일약품 (2048134872)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명원일약품
영문명WONIL Medical CO. LTD
대표자이한우
사업자등록번호2048134872
법인등록번호1101111254666
설립일1996.03.26
종업원수17명

V.Workforce

17

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW1,269.620211,353.120221,621.120231,750.220241,776.12025
영업이익100M KRW5.9202110.9202212.2202321.520247.42025
순이익100M KRW7.2202111.8202212.2202314.620245.22025
Item20252024202320222021
자산총계632.6억원515억원598.6억원505.6억원461.7억원
부채총계472.6억원360.3억원458.4억원377.7억원345.6억원
자본총계160억원154.7억원140.2억원127.9억원116.1억원
매출액1,776.1억원1,750.2억원1,621.1억원1,353.1억원1,269.6억원
영업이익7.4억원21.5억원12.2억원10.9억원5.9억원
순이익5.2억원14.6억원12.2억원11.8억원7.2억원

VII.Financial Ratios

FY2025 basis

0.42%

영업이익률

0.29%

순이익률

0.82%

ROA

3.26%

ROE

295.47%

부채비율

25.29%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

원일약품 투심보고서 | Alpha Lenz